XOMA Royalty (XOMA) Non-Current Assets (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Non-Current Assets came in at $153.1 million in Q1 2026, up 53.84% year-on-year from $99.5 million in Q1 2025, and down 1.5% quarter-over-quarter from $155.4 million in Q4 2025.
XOMA Royalty (XOMA) Non-Current Assets (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Non-Current Assets across 17 years of filings, most recently posting $153.1 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $153.1 million, up 53.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $579.5 million (up 70.15% YoY), and the FY2025 annual result was $155.4 million, up 62.47% from the prior year.
- Non-Current Assets came in at $153.1 million for Q1 2026 at XOMA Royalty, down from $155.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $155.4 million in Q4 2025 to a low of $64.3 million in Q3 2024.
- The 5-year median for Non-Current Assets is $87.2 million (2023), against an average of $94.4 million.
- Across the five-year window, Non-Current Assets declined 28.21% in 2024 and jumped 137.01% in 2025, its largest moves.
- XOMA Royalty's Non-Current Assets stood at $79.1 million in 2022, then slipped by 17.87% to $65.0 million in 2023, then surged by 47.22% to $95.7 million in 2024, then surged by 62.47% to $155.4 million in 2025, then fell by 1.5% to $153.1 million in 2026.
- The last three Non-Current Assets figures came in at $153.1 million (Q1 2026), $155.4 million (Q4 2025), and $152.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 62,953.78 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 39.71 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 153.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.11 Mn |
| Dec 31, 2025 | 155.44 Mn |
| Sep 30, 2025 | 152.44 Mn |
| Jun 30, 2025 | 118.53 Mn |
| Mar 31, 2025 | 99.53 Mn |
| Dec 31, 2024 | 95.67 Mn |
| Sep 30, 2024 | 64.32 Mn |
| Jun 30, 2024 | 81.08 Mn |
| Mar 31, 2024 | 72.53 Mn |
| Dec 31, 2023 | 64.99 Mn |
| Sep 30, 2023 | 89.59 Mn |
| Jun 30, 2023 | 87.24 Mn |
| Mar 31, 2023 | 88.59 Mn |
| Dec 31, 2022 | 79.13 Mn |
| Sep 30, 2022 | 66.39 Mn |
| Jun 30, 2022 | 66.96 Mn |
| Mar 31, 2022 | 69.55 Mn |
| Dec 31, 2021 | 69.59 Mn |
| Sep 30, 2021 | 55.63 Mn |
| Jun 30, 2021 | 48.50 Mn |